Peregrine begins investigator-sponsored trial with bavituximab
The Phase I dose-escalation trial will enrol up to 18 patients with bavituximab in combination with the chemotherapeutic agent capecitabine and radiation therapy. The study principal investigator, the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.